Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/Day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).

Inclusion criteria:

• Patient must be diagnosed with ADHD.

Exclusion Criteria:

• Patient has a current or past history of seizure disorder, brain injury, anorexia nervosa or bulimia.
• Patient has a current diagnosis of Major Depressive Disorder (MDD).
• Patient has a current primary diagnosis of, or received treatment for, Panic Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD) or Acute Stress Disorder within the previous 12 months.
• Patient has a lifetime diagnosis of bipolar disorder, schizophrenia or other psychotic disorders.
• Patient has a positive urine test at screening for presence of illicit drugs or alcohol abuse during the past 12 months.